UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2012

Oxygen Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)


Delaware
 
001-34600
 
26-2593535
(State or other jurisdiction of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

ONE Copley Parkway, Suite 490
Morrisville, NC 27560
(Address of principal executive offices) (Zip Code)

919-855-2100
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
Item 1.01
Entry into a Material Definitive Agreement

As previously disclosed, on December 8, 2011, Oxygen Biotherapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Buyers”) for the issuance and sale of units (the “Units”) consisting of an aggregate of $7.5 million of Series A Convertible Preferred Stock, $0.0001 par value per share (the “Preferred Stock”) and warrants (the “Warrants”) to purchase approximately 1,689,192 shares of Common Stock, par value $0.0001 per share.  The SPA provided for the sale of Units in two installments.  The first installment of $3.5 million closed on December 12, 2011, and the second installment (the “Additional Closing”) of $4.0 million was scheduled to have occurred in June 2012, subject to certain closing conditions, including that the Company would have sufficient capacity under NASDAQ Stock Market rules relating to issuances of more than 20% of the Company’s outstanding Common Stock without stockholder approval to ensure delivery of all shares in the Additional Closing (the “NASDAQ 20% Condition”).

Because the NASDAQ 20% Condition was not satisfied, on June 14, 2012, the Company entered into an Amendment Agreement with each of the Buyers that, among other things, divides the Additional Closing into a first additional closing (the “First Additional Closing”) to occur on or about June 15, 2012 in the amount of $2,500,000 and a second additional closing (the “Second Additional Closing”) to occur on or about September 14, 2012 in the amount of $1,500,000.  Each of the First Additional Closing and Second Additional Closing is subject to customary closing conditions.  The Second Additional Closing is also subject to certain additional closing conditions, including that the Company will have obtained stockholder approval for the issuances to the Buyers in order to satisfy the NASDAQ 20% Condition, and that the Company will have entered into an agreement with each Buyer providing such Buyer with an additional investment opportunity in Company securities similar to those previously issued to the Buyer.  Under the SPA, as amended, the Company will be prohibited from engaging in certain transactions with respect to shares of its Common Stock until 120 days after the date of the First Additional Closing, subject to certain specified exceptions.  Except as specifically set forth in the Amendment Agreements, the SPA and other documents related to the Company’s December 2011 financing remain in full force and effect.

The Form of Amendment Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K.  The foregoing summary of the terms of the Amendment Agreements is subject to, and qualified in its entirety by, the Form of Amendment Agreement attached hereto, which is incorporated herein by reference.

The Units were offered and sold pursuant to a prospectus supplement dated December 8, 2011 and an accompanying prospectus dated April 14, 2010, pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-165733). This Current Report on Form 8-K is neither an offer to sell nor a solicitation of an offer to buy any of the Company’s securities.

Item 8.01
Other Events

On June 15, 2012, the Company issued a press release announcing the Amendment Agreements described above under Item 1.01 of this Current Report on Form 8-K.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits

(d)           Exhibits

Exhibit No.
 
Description
Exhibit 10.1
 
Form of Amendment Agreement
Exhibit 99.1
 
Press Release dated June 15, 2012

 
2

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Oxygen Biotherapeutics, Inc.  
       
Date: June 15, 2012
By:
/s/ Michael B. Jebsen  
    Michael B. Jebsen  
   
Chief Financial Officer and Interim Chief Executive Officer
       

 
3

 
 
Exhibit Index

Exhibit No.
 
Description
Exhibit 10.1
 
Form of Amendment Agreement
Exhibit 99.1
 
Press Release dated June 15, 2012
 

4

 
Exhibit 10.1
 
FORM OF AMENDMENT AGREEMENT
 
AMENDMENT AGREEMENT (the “ Amendment Agreement ”), dated as of June 14, 2012, by and among Oxygen Biotherapeutics, Inc., a Delaware corporation, with headquarters located at ONE Copley Parkway, Suite 490, Morrisville, NC 27560 (the “ Company ”), and [____] (the “ Buyer ”), which is a party to that certain Securities Purchase Agreement, dated as of December 8, 2011 (the “ Purchase Agreement ”), by and among the Company, the Buyer and another investor thereunder (the “ Additional Buyer ”). Capitalized terms used herein that are not otherwise defined herein shall have the meanings given them in the Purchase Agreement.
 
WHEREAS :
 
A.   The Purchase Agreement provides that the Company shall sell to the Buyer and the Additional Buyer, and the Buyer and Additional Buyer shall purchase from the Company, subject to certain closing conditions, certain Additional Preferred Shares and Additional Warrants on the Additional Closing Date;
 
B.   As of the Additional Closing Date, certain of the closing conditions set forth in the Purchase Agreement have not been satisfied;
 
C.   To facilitate the sale and issuance of the Additional Preferred Shares and Additional Warrants, the Company and the Buyer wish to amend the Purchase Agreement to provide for additional closings thereunder as set forth below; and
 
D.   Section 9(e) of the Purchase Agreement provides that the Purchase Agreement may be amended by an instrument in writing signed by the Company and the holders of at least a majority of the Registrable Securities issued and issuable under the Purchase Agreement.
 
NOW, THEREFORE , the Company and the Buyer hereby agree as follows:
 
1.   Amendment of Purchase Agreement
 
(a)   Section 1(a)(ii) of the Purchase Agreement is hereby deleted in its entirety and amended and restated as follows:
 
“(ii)   Additional Closing .  Subject to the satisfaction (or waiver) of the conditions set forth in Sections 1(d), 6(b) and 7(b) below, the Company shall issue and sell to each Buyer, and each such Buyer severally, but not jointly, agrees to purchase from the Company on (a) the First Additional Closing Date (as defined below), (i) the number of Additional Preferred Shares as is set forth opposite such Buyer’s name in column (3)(b) on the Schedule of Buyers and (ii) Additional Warrants to acquire up to that number of Additional Warrant Shares as is set forth opposite such Buyer’s name in column (4)(b) on the Schedule of Buyers (the “ First Additional Closing ”) and (b) the Second Additional Closing Date (as defined below), (i) the number of Additional Preferred Shares as is set forth opposite such Buyer’s name in column (3)(c) on the Schedule of Buyers and (ii) Additional Warrants to acquire up to that number of Additional Warrant Shares as is set forth opposite such Buyer’s name in column (4)(c) on the Schedule of Buyers (the “ Second Additional Closing ” and together with the First Additional Closing, each an “ Additional Closing ”). The Initial Closing, the First Additional Closing, and the Second Additional Closing are each referred to herein as a “ Closing ”, and, whenever the context requires, each reference in this Agreement to “the Additional Closing” or words of like import shall mean and be a reference to “the applicable Additional Closing.””
 
 
 

 
 
(b)   Section 1(d) of the Purchase Agreement is hereby deleted in its entirety and amended and restated as follows:
 
“(d)   Additional Closing Date .  The date and time of the First Additional Closing (the “ First Additional Closing Date ”) shall be 10:00 a.m., New York City time, on June 15, 2012 (or, in any case, such other date and time as is mutually agreed to by each Buyer and the Company), and the date and time of the Second Additional Closing (the “ Second Additional Closing Date ”, and together with the First Additional Closing Date, each an “ Additional Closing Date ”) shall be 10:00 a.m., New York City time, on September 14, 2012 (or, in any case, such other date and time as is mutually agreed to by each Buyer and the Company), in each case subject to satisfaction (or waiver) of the conditions to Additional Closing set forth in Sections 6(b) and 7(b) and the conditions contained in this Section 1(d).  The Initial Closing Date, the First Additional Closing Date, and the Second Additional Closing Date are each referred to herein as a “ Closing Date ”, and, whenever the context requires, each reference in this Agreement to “the Additional Closing Date” or words of like import shall mean and be a reference to “the applicable Additional Closing Date.”  Subject to the requirements of Sections 6(b) and 7(b) and the conditions contained in this Section 1(d), on (i) the First Additional Closing Date, each Buyer shall purchase, and the Company shall sell to each such Buyer the Additional Preferred Shares and Additional Warrants contemplated to be purchased by such Buyer as set forth in column 3(b) and column 4(b) of the Schedule of Buyers, respectively, and (ii) the Second Additional Closing Date, each Buyer shall purchase, and the Company shall sell to each such Buyer the Additional Preferred Shares and Additional Warrants contemplated to be purchased by such Buyer as set forth in column 3(c) and column 4(c) of the Schedule of Buyers, respectively. If the Company has not satisfied one or more conditions to the applicable Additional Closing, subject to the conditions set forth in Section 6(b), each Buyer may elect, by written notice to the Company to waive any such condition or conditions, and may elect to purchase all or any portion of the Additional Preferred Shares and Additional Warrants contemplated to be purchased by such Buyer as set forth in the immediately preceding sentence.  The location of each Additional Closing shall be at the offices of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022.  Notwithstanding anything herein to the contrary, if the Second Additional Closing does not occur by September 30, 2012 (or such other date as is mutually agreed to by each Buyer and the Company) (x) but the Company has granted the Option (as defined below) to the Buyers by such date, then on September 30, 2012 (or such other date as is mutually agreed to by each Buyer and the Company) or (y) and the Company has not granted the Option to the Buyers by such date, then on December 31, 2012 (or such other date as is mutually agreed to by each Buyer and the Company) (the “ Second Additional Closing Termination Date ”) (i) the Company’s obligation to sell any Additional Preferred Shares and Additional Warrants, and the Buyer’s obligation to purchase such Additional Preferred Shares and Additional Warrants, shall terminate, and (ii) any “lock-up” or similar provisions contained in (a) Section 4(o)(ii) below, (b) Section 2(a)(xxiv)(J), the first sentence of Section 11, the third, fourth and sixth sentences of Section 12, Section 14(c), and Section 14(e) of the Certificate of Designations, and (c) in each of the Lock-Up Agreements (as defined below) (collectively, the “ Lock-Up Provisions ”) shall be deemed to have expired on the Second Additional Closing Termination Date.  In addition, if pursuant to this paragraph the Buyers, in the aggregate as of the Second Additional Closing Date, have elected to purchase less than an aggregate of 1,500 Additional Preferred Shares at the Second Additional Closing, (i) the Company’s obligation to sell any Additional Preferred Shares and Additional Warrants not elected to be purchased, and the Buyer’s obligation to purchase such Additional Preferred Shares and Additional Warrants, shall terminate, and (ii) the Lock-Up Provisions shall be deemed to have expired on the Second Additional Closing Date.”
 
 
2

 
 
(c)   Section 4(o)(ii) of the Purchase Agreement is hereby deleted in its entirety and amended and restated as follows:
 
“From the date hereof until the later of (i) one hundred and twenty (120) days immediately following the First Additional Closing Date and (ii) December 31, 2012 in the event the Company has not granted the Option to the Buyers by September 30, 2012 (the “ Trigger Date ”), the Company will not, directly or indirectly, offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other disposition of) any of its equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any circumstances, convertible into or exchangeable or exercisable for shares of Common Stock or Common Stock Equivalents (any such offer, sale, grant, disposition or announcement being referred to as a “ Subsequent Placement ”), or be party to any solicitations or negotiations with regard to the foregoing.”
 
(d)   Section 4(p) of the Purchase Agreement is hereby amended to replace the reference to “October 15, 2012” in the first sentence with “September 14, 2012”.
 
(e)   Section 7(b)(xv) of the Purchase Agreement is hereby deleted in its entirety and amended and restated as follows:
 
“(xv)  With respect to the Second Additional Closing, the Stockholder Approval shall have been obtained.”
 
(f)     Section 7(b)(xviii) of the Purchase Agreement is hereby deleted in its entirety and amended and restated as follows:
 
“(xviii) The Company shall be able to issue all shares of Common Stock underlying (i) the Additional Preferred Shares to be issued on the applicable Additional Closing Date (assuming, for purposes of this closing condition, that such Additional Preferred Shares are convertible into Common Stock at 80% of the lower of (A) the VWAP (as defined in the Certificate of Designations) of the Common Stock on the Trading Day immediately preceding such Additional Closing Date and (B) the Company Conversion Price (as defined in the Certificate of Designations, but calculated as of the Trading Day immediately preceding such Additional Closing Date instead of the Installment Settlement Date)) and (ii) the Additional Warrants to be issued on the applicable Additional Closing Date without (x) breaching, or otherwise being limited by, the Exchange Cap (as defined in the Certificate of Designations), to the extent then applicable, or (y) triggering a failure by the Company to have a sufficient number of shares of Common Stock authorized for such issuance.”
 
 
3

 
 
(g)     A new Section 7(b)(xxi) of the Purchase Agreement is hereby added as follows:
 
“(xxi) with respect to the Second Additional Closing, the Company shall have entered into an agreement with such Buyer providing such Buyer with the opportunity to invest an additional $1,250,000 in Company securities of like tenor as the Preferred Shares and Warrants (with the same 50% Warrant coverage as contemplated for each Closing under this Agreement) on terms reasonably acceptable to the Company and such Buyer (the “ Option ”).”
 
(h)   The Schedule of Buyers attached to the Purchase Agreement is hereby deleted in its entirety and replaced with the Schedule of Buyers attached hereto.
 
2.   Effectiveness .  This Amendment Agreement shall become effective when, and only when, the Company and the Buyer shall have executed and delivered this Amendment Agreement and the Company and the Additional Buyer have executed and delivered an amendment agreement in substance identical to this Amendment Agreement (the “ Additional Amendment Agreement ”).  Upon effectiveness of this Amendment Agreement and the Additional Amendment Agreement, this Amendment Agreement and the Additional Amendment Agreement shall be considered one and the same “instrument” for purposes of Section 9(e) of the Purchase Agreement and shall amend the Purchase Agreement and the other Transaction Documents as provided herein.  The Company hereby represents and warrants that none of the terms offered to the Additional Buyer [INSERT IN NON-LEAD INVESTOR’S AMENDMENT AGREEMENT] [(other than with respect to fee reimbursement of the Additional Buyer by the Company)] with respect to the Additional Amendment Agreement is more favorable to the Additional Buyer than those of the Buyer and this Amendment Agreement.  From and after the date this Amendment Agreement becomes effective, the Company shall not amend this Amendment Agreement and/or the Additional Amendment Agreement except with the consent of the Company and the Required Holders.
 
3.   Disclosure of Transactions and other Material Information .  On or before 8:30 a.m., New York City time, on the first Business Day following the execution of this Amendment Agreement, the Company shall file a Current Report on Form 8-K describing the terms of the transactions contemplated by this Amendment Agreement and the amendment entered into by the Additional Buyer in the form required by the 1934 Act and attaching a form of this Amendment (including all attachments, the “ 8-K Filing ”).  As of immediately following the filing of the 8-K Filing with the SEC, the Buyer shall not be in possession of any material, nonpublic information received from the Company, or any of its officers, directors, employees or agents, that is not disclosed in the 8-K Filing or in prior filings with the SEC.  The Company shall not, and shall cause each of its officers, directors, employees and agents, not to, provide any buyer with any material, nonpublic information regarding the Company from and after the filing of the 8-K Filing with the SEC without the express written consent of the Buyer.  If the Company or any of its or their officers, directors, employees, stockholders or agents delivers any material, non-public information to the Buyer without the Buyer’s consent, the Company hereby covenants and agrees that the Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public information.
 
 
4

 
 
4.   Fees .  [INSERT IN LEAD INVESTOR’S AMENDMENT AGREEMENT] [Subject to Section 8 of the Purchase Agreement, at each Additional Closing, the Company shall pay an expense allowance to the Buyer or its designee(s) for all actual costs and expenses incurred in connection with the transactions contemplated by this Amendment Agreement, the Transaction Documents and the Option (including all reasonable legal fees and disbursements in connection therewith and documentation and implementation of the transactions contemplated by the Transaction Documents) in an amount not to exceed $40,000, which amount, at the option of the Buyer, may be withheld by the Buyer from its purchase price at each Additional Closing.]  The Company shall be responsible for the payment of any placement agent’s fees, financial advisory fees, or broker’s commissions, if any, (other than for persons engaged by the Buyer) relating to or arising out of the transactions contemplated hereby.  The Company shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating to any such payment.
 
5.   Counterparts .  This Amendment Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a signature transmitted by facsimile or electronic PDF shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or PDF signature.
 
6.   Reference to and Effect on the Purchase Agreement .  From and after the effective date hereof, each reference in the Purchase Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Purchase Agreement, and each reference in any other Transaction Documents to the “Securities Purchase Agreement,” “thereunder,” “thereof” or words of like import referring to the Purchase Agreement, shall mean and be a reference to the Purchase Agreement as amended hereby.  Except as specifically provided herein, the Purchase Agreement and the other Transaction Documents shall remain in full force and effect.  Except as specifically provided above, the execution, delivery and effectiveness of this Amendment Agreement shall not operate as a waiver of any right, power or remedy of the Company or Buyer under the Purchase Agreement or any of the Transaction Documents.
 
7.   References in the Purchase Agreement and Certain Other Translation Documents .  From and after the effective date hereof, for the avoidance of doubt, (i) any references in any of the Transaction Documents to “the Additional Closing” shall refer instead the applicable Additional Closing, an Additional Closing or each Additional Closing, as the context dictates, (ii) any references in any of the Transaction Documents to “the Additional Closing Date” shall refer instead the applicable Additional Closing Date, an Additional Closing Date or each Additional Closing Date, as the context dictates, (iii) any references in the Certificate of Designations to “the Subsequent Issuance Date” shall refer instead to each applicable Subsequent Issuance Date, a Subsequent Issuance Date or each Subsequent Issuance Date, as the context dictates and (iv) any references in the Certificate of Designations to “the applicable Issuance Date” shall refer instead to the Initial Issuance Date or the applicable Subsequent Issuance Subsequent Issuance Date, as applicable.
 
 
5

 
 
8.   Governing Law .  This Amendment Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws provisions thereof.
 
9.   Independent Nature of Obligations and Rights .  Nothing contained herein, and no action taken by the Buyer pursuant hereto, shall be deemed to constitute the Buyer and the Additional Buyer as, and the Company acknowledges, and the Buyer confirms, that the Buyer and Additional Buyer do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Buyer and Additional Buyer are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the transactions contemplated hereby and the Company acknowledges, and the Buyer confirms, that the Buyer and the Additional Buyer are not acting in concert or as a group with respect to such obligations or the transactions contemplated hereby.  The Company acknowledges and the Buyer confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors.  The Buyer shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Amendment Agreement, and it shall not be necessary for any Additional Buyer to be joined as an additional party in any proceeding for such purpose.
 
[Signature Page Follows]
 
 
6

 
 
IN WITNESS WHEREOF, the Buyer and the Company have caused their respective signature page to this Amendment Agreement to be duly executed as of the date first written above.
 
 
COMPANY:
 
     
  OXYGEN BIOTHERAPEUTICS, INC.  
       
 
By:
/s/   
    Name   
    Title   
       

 
 
[Signature Page to Amendment Agreement]
 
 
 
 

 
 
IN WITNESS WHEREOF, the Buyer and the Company have caused their respective signature page to this Amendment Agreement to be duly executed as of the date first written above.
 
 
 
BUYER:
 
     
  [INVESTOR]  
       
  By:    
       
       
 
By:
   
    Name:  
    Title:  
       
 
 
 
[Signature Page to Amendment Agreement]
 
 
 
 

 
 
SCHEDULE OF BUYERS
 
(1)
(2)
(3)(a)
3(b)
3(c)
(4)(a)
(4)(b)
(4)(c)
(5)
(6)
Buyer
Address and
Facsimile Number
Number of Initial Preferred Shares
 
Maximum Number of Additional Preferred  Shares (First Additional Closing)
 
Maximum Number of Additional Preferred  Shares (Second Additional Closing)
Number of Initial Warrant Shares
Maximum Number of Additional Warrant Shares (First Additional Closing)
Maximum Number of Additional Warrant Shares (Second Additional Closing)
Initial Purchase Price
Legal Representative’s Address and Facsimile Number
                   
                   
                   

 

Exhibit 99.1
 
 
Contact:
Ellen Corliss
   SVP, Corporate Communications
& Investor Relations
(919) 855-2112

Oxygen Biotherapeutics Announces Expected Closing on Second Installment of December 2011 Financing and Amends Agreement to Allow for a Third Tranche Later This Year Pending Shareholder Approval
 
 
MORRISVILLE, NC, June 15, 2012 – Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that it has entered into definitive agreements with institutional investors to amend the terms of the Company’s previously announced $7.5 million offering of registered shares of Series A Convertible Preferred Stock, par value $0.0001 per share, and registered warrants to purchase shares of the Company’s common stock, par value $0.0001 per share.  The transaction, which was announced in December 2011, was originally scheduled to fund in two installments.  The first installment of $3.5 million closed on December 12, 2011, and the second installment of $4.0 million was scheduled to close in June 2012, subject to certain closing conditions.  One of these conditions required the Company to have sufficient capacity to ensure delivery of all shares in the second installment under NASDAQ Stock Market rules relating to issuances of more than 20% of the Company’s outstanding Common Stock without stockholder approval.
 
Because the Company calculated that the closing condition relating to the NASDAQ 20% threshold was not going to be satisfied, the Company and the institutional investors yesterday agreed to divide the originally scheduled $4.0 million second installment into a $2.5 million installment and a $1.5 million installment.  The $2.5 million installment is scheduled to close on or about June 15, 2012, and the $1.5 million installment is scheduled to close on or about September 14, 2012, pending shareholder approval. Each installment is subject to the satisfaction of certain closing conditions.
 
“While we have not yet surpassed the NASDAQ threshold, we may be over it when the original agreement ends in December 2012.  Therefore, we diligently negotiated this amendment which is beneficial to all parties involved and provides us the time needed to seek approval from our shareholder base as NASDAQ requires,” said Michael Jebsen, Interim Chief Executive Officer, President and Chief Financial Officer of Oxygen Biotherapeutics.  “We are pleased that these institutional investors have been supportive of our company and were willing to work with us to fund the entire investment, pending approval from shareholders at the Annual Meeting which is expected to occur prior to September 14 th .”
 
 
 

 
 
Exhibit 99.1
 
The securities described above were offered by the Company pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the “SEC”).  A prospectus supplement related to the offering was filed with the SEC on December 9, 2011. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
 
Copies of the final prospectus supplement and accompanying base prospectus may be obtained at the SEC's website at www.sec.gov.
 
This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company’s securities. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation, or sale is unlawful. The terms and conditions of the transactions described in this press release are qualified in their entirety by reference to the transaction documents, which have been filed with the Securities and Exchange Commission on Form 8-K.

About Oxygen Biotherapeutics, Inc.

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The Company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier product that is being formulated for both intravenous and topical delivery for use in treating traumatic brain injury, decompression sickness, and dermatological indications.  In addition, the Company has commercialized its DERMACYTE® line of oxygen-rich skin care products. See www.oxybiomed.com or www.DermacyteUS.com for more information.

Caution Regarding Forward-Looking Statements
 
This news release contains certain forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s judgment as of the date of this release. These statements include those regarding shareholder approval of the financing and the closing of the additional installments of the financing, all as described above. The forward-looking statements are subject to a number of risks and uncertainties, including those described herein and in our filings with the Securities and Exchange Commission, including in the current Annual Report on Form 10-K filed on July 15, 2011, and the Quarterly Reports on Form 10-Q filed on September 19, 2011, December 15, 2011, and March 15, 2012. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.